Portuguese version of Duke Religious Index: DUREL

-

Mandibular-Lingual Repositioning Device - MLRD: preliminary results of 8 patients with Obstructive Sleep Apnea Syndrome - OSAS

Dental devices have been employed in the treatment of snoring and obstructive sleep apnea syndrome (OSAS) of mild to moderate degrees. The authors disclose the preliminary results in 8 patients with clinically diagnosed obstructive sleep apnea polisomnographically confirmed and treated with a dental device (Mandibular-Lingual Repositioning Device - MLRD) developed by one of the authors (RCB). Cephalometrics was performed before usage of MLRD, Epworth Sleepiness Scale (ESS) tests were conducted before and after the MLRD and a questionnaire that subjectively qualified the Overall Subjective Improvement of the patient (OSI) was filled out. The tests were repeated 4 weeks after the application of the MLRD. The average subjective overall improvement was 73.75% and the Epworth Sleepiness Scale was 13.88 (pre - MLRD) and 6.63 (post - MLRD) representing a significant statistical variation (p=0.05). The authors discuss probable factors involved in the improvement of the subjective measurements of excessive sleepiness

Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts

This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized by abnormal sensations mostly but not exclusively in the legs which worsen in the evening and are improved by motion of the affected body part. its diagnosis is solely based on clinical findings. Therapeutic agents with efficacy supported by Class I studies are dopamine agonists, levodopa and gabapentine. Class 11 studies support the use of slow release valproic acid, clonazepan and oxycoclone. The GBE-SPI recommendations for management of SPI are sleep hygiene, withdrawal of medications capable of worsening the condition, treatment of comorbidities and pharmacological agents. The first choice agents are dopaminergic drugs, second choice are gabapentine or oxycodone, and the third choice are clonazepan or slow release valproic acid.Univ Sao Paulo, Hosp Clin, Dept Neurol, Sao Paulo, BrazilHosp Israelita Albert Einstein, Inst Cerebro, Sao Paulo, BrazilPratica privada, Curitiba, Parana, BrazilPractica Privada, Rio De Janeiro, BrazilUniv Fed Minas Gerais, Dept Clin Med, Belo Horizonte, MG, BrazilUniv Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Sao Paulo, BrazilUNESP, Dept Neurol, Botucatu, SP, BrazilUFCE, Fortaleza, Ceara, BrazilPractica Privada, Porto Alegre, RS, BrazilUniv Fed Goias, Hosp Clin, Serv Neurol, Goiania, Go, BrazilUniv Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Sao Paulo, BrazilWeb of Scienc